Sign In
Buy DVAX
$15.50
+0 (+0%)
At Close: May 08, 2026
Dynavax: Expect Share Price Gains When Heplisav Sales Get Back On Track
05:40am, Monday, 14'th Sep 2020
Under new management and having finally secured approval for its Hepatitis B vaccine Heplisav-B, Dynavax share price exceeded $11 in July.
Coronavirus Vaccine Roundup, Early September
07:39am, Friday, 04'th Sep 2020
Taking a looking at the COVID-19 vaccine development landscape across various classes, including viral vectors, genetic vaccines, recombinant protein vaccines, attenuated virus vaccines, inactivated v
9 Reasons Why The Race For Major COVID-19 Vaccine Revenues Has Greatly Narrowed
10:06am, Wednesday, 02'nd Sep 2020
The huge amount of Operation Warp Speed funding for its six vaccines has helped them become somewhat dominant leaders in the race for a sizable share of the market.
Dynavax's Restructuring: A Work In Progress
04:22am, Wednesday, 26'th Aug 2020
Dynavax has finally found a home for its discarded cancer therapies, albeit one with little near- or mid-term upside.
Flavourless Recipe For Dynavax Technologies Is Hurting Shareholders
12:27pm, Tuesday, 25'th Aug 2020
Dynavax Technologies has left a sour taste in investors mouths giving away 36.5% over the previous month and over -93% in price returns since inception.
Dynavax: Ready To Return To Bullish
10:04am, Monday, 24'th Aug 2020
After months of remaining neutral on the ticker, I am returning to a bullish outlook for DVAX in anticipation HEPLISAV-B's numbers improve.
GlaxoSmithKline: Attention Is Now Shifting To Vaccine Manufacturing
09:39am, Friday, 21'st Aug 2020
Current state of COVID-19 vaccine production indicates that GSK is both in vaccine development and manufacturing.
Why Pfizer's 4% Yield Is Your Best Covid-19 Vaccine Play
12:24pm, Thursday, 13'th Aug 2020
I demonstrate why Pfizer is the best choice for dividend investors playing the Covid-19 vaccine theme.
Dynavax Announces Grant to Scale up CpG 1018 Adjuvant Capacity to Support the Global COVID-19 Response
12:00pm, Thursday, 13'th Aug 2020
EMERYVILLE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today annou
Understanding Dynavax Technologies's Unusual Options Activity
04:12pm, Wednesday, 12'th Aug 2020
Shares of Dynavax Technologies (NASDAQ: DVAX) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved down to $6.79. * Sentiment: BEARISH * Option T
Finally, Some Good News for Dynavax Technologies
02:07pm, Wednesday, 12'th Aug 2020
This biotech has a vaccine for treating hepatitis B and is now tackling COVID-19. But it's still valued at less than $1 billion.
Why Dynavax Technologies, Heat Biologics, and Inovio Pharmaceuticals Are Cratering Today
03:27pm, Tuesday, 11'th Aug 2020
Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.
Implied Volatility Surging for Dynavax (DVAX) Stock Options
01:14pm, Tuesday, 11'th Aug 2020
Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately.
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
12:38pm, Monday, 10'th Aug 2020
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
Dynavax Technologies (DVAX) Reports Q2 Loss, Misses Revenue Estimates
12:20am, Friday, 07'th Aug 2020
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -12.50% and -53.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
